Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Endometriosis Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Endometriosis Overview | 12 | 1 |
| Pipeline Products for Endometriosis Comparative Analysis | 13 | 1 |
| Endometriosis Therapeutics under Development by Companies | 14 | 2 |
| Endometriosis Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Endometriosis Pipeline Products Glance | 17 | 4 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Unknown Stage Products | 20 | 1 |
| Endometriosis Products under Development by Companies | 21 | 3 |
| Endometriosis Products under Investigation by Universities/Institutes | 24 | 1 |
| Endometriosis Companies Involved in Therapeutics Development | 25 | 23 |
| AbbVie Inc | 25 | 1 |
| Addex Therapeutics Ltd | 26 | 1 |
| APAvadis Biotechnologies Srl | 27 | 1 |
| Astellas Pharma Inc. | 28 | 1 |
| Bayer AG | 29 | 1 |
| Dongkook Pharmaceutical Co., Ltd. | 30 | 1 |
| ElexoPharm GmbH | 31 | 1 |
| EndoCeutics, Inc. | 32 | 1 |
| Enteris BioPharma, Inc. | 33 | 1 |
| Euroscreen S.A. | 34 | 1 |
| Evotec AG | 35 | 1 |
| Forendo Pharma Limited | 36 | 1 |
| GlaxoSmithKline Plc | 37 | 1 |
| Kissei Pharmaceutical Co., Ltd. | 38 | 1 |
| Lipicard Technologies Limited | 39 | 1 |
| Luye Pharma Group Ltd. | 40 | 1 |
| Nippon Shinyaku Co., Ltd. | 41 | 1 |
| Orphagen Pharmaceuticals, Inc. | 42 | 1 |
| Philogen S.p.A. | 43 | 1 |
| Repros Therapeutics Inc. | 44 | 1 |
| SK Chemicals Co., Ltd. | 45 | 1 |
| Takeda Pharmaceutical Company Limited | 46 | 1 |
| ValiRx Plc | 47 | 1 |
| Endometriosis Therapeutics Assessment | 48 | 12 |
| Assessment by Monotherapy Products | 48 | 1 |
| Assessment by Combination Products | 49 | 1 |
| Assessment by Target | 50 | 3 |
| Assessment by Mechanism of Action | 53 | 3 |
| Assessment by Route of Administration | 56 | 2 |
| Assessment by Molecule Type | 58 | 2 |
| Drug Profiles | 60 | 59 |
| acolbifene hydrochloride + GnRH Agonist + prasterone Drug Profile | 60 | 1 |
| ASP-1707 Drug Profile | 61 | 1 |
| BAY-1128688 Drug Profile | 62 | 1 |
| bentamapimod Drug Profile | 63 | 1 |
| Drug to Inhibit C-Jun for Endometriosis Drug Profile | 64 | 1 |
| Drugs for Endometriosis Drug Profile | 65 | 1 |
| Drugs for Endometriosis and Uterine Fibroids Drug Profile | 66 | 1 |
| elagolix sodium Drug Profile | 67 | 4 |
| epelsiban besylate Drug Profile | 71 | 2 |
| ESN-364 Drug Profile | 73 | 2 |
| EVE-104 Drug Profile | 75 | 1 |
| FP-5677 Drug Profile | 76 | 1 |
| goserelin biosimilar Drug Profile | 77 | 1 |
| goserelin ER Drug Profile | 78 | 1 |
| KLH-2109 Drug Profile | 79 | 1 |
| leuprolide acetate Drug Profile | 80 | 1 |
| LT-6121 Drug Profile | 81 | 1 |
| MIA-602 Drug Profile | 82 | 1 |
| Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis Drug Profile | 83 | 1 |
| NS-580 Drug Profile | 84 | 1 |
| Peptides for Endometriosis and Hepatic Tumor Drug Profile | 85 | 1 |
| Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor Drug Profile | 86 | 1 |
| PGL-2001 Drug Profile | 87 | 1 |
| Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome Drug Profile | 88 | 1 |
| relugolix Drug Profile | 89 | 2 |
| SKI-2670 Drug Profile | 91 | 1 |
| Small Molecule to Antagonize FSH Receptor for Women's Health Drug Profile | 92 | 1 |
| Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology Drug Profile | 93 | 1 |
| Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis Drug Profile | 94 | 1 |
| Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease Drug Profile | 95 | 1 |
| Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis Drug Profile | 96 | 1 |
| Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers Drug Profile | 97 | 1 |
| Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis Drug Profile | 98 | 1 |
| SR-16234 Drug Profile | 99 | 1 |
| Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology Drug Profile | 100 | 1 |
| telapristone acetate Drug Profile | 101 | 8 |
| Tetravil Drug Profile | 109 | 2 |
| triptorelin biosimilar Drug Profile | 111 | 1 |
| VAL-201 Drug Profile | 112 | 4 |
| vilaprisan Drug Profile | 116 | 1 |
| VPE-001 Drug Profile | 117 | 1 |
| VPEA-004 Drug Profile | 118 | 1 |
| Endometriosis Dormant Projects | 119 | 2 |
| Endometriosis Discontinued Products | 121 | 1 |
| Endometriosis Product Development Milestones | 122 | 9 |
| Featured News &Press Releases | 122 | 1 |
| Aug 05, 2016: Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis | 122 | 1 |
| Jul 06, 2016: ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis | 122 | 1 |
| Mar 31, 2016: ValiRx is exhibiting and presenting at the prestigious AACR | 123 | 1 |
| Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis | 123 | 1 |
| Dec 21, 2015: Repros Updates Proellex Program | 124 | 1 |
| Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA | 124 | 1 |
| Feb 26, 2015: New Endometriosis Patent Grant for ValiRx | 125 | 1 |
| Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications | 126 | 1 |
| Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis | 126 | 1 |
| Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting | 127 | 1 |
| Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 | 128 | 1 |
| Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples | 128 | 1 |
| Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 | 128 | 1 |
| Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 | 129 | 1 |
| Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis | 129 | 2 |
| Appendix | 131 | 2 |
| Methodology | 131 | 1 |
| Coverage | 131 | 1 |
| Secondary Research | 131 | 1 |
| Primary Research | 131 | 1 |
| Expert Panel Validation | 131 | 1 |
| Contact Us | 131 | 1 |
| Disclaimer | 132 | 1 |